472 related articles for article (PubMed ID: 21205831)
1. Poly(ADP-ribose) polymerase (PARP) inhibitors: Exploiting a synthetic lethal strategy in the clinic.
Yap TA; Sandhu SK; Carden CP; de Bono JS
CA Cancer J Clin; 2011; 61(1):31-49. PubMed ID: 21205831
[TBL] [Abstract][Full Text] [Related]
2. [PARP inhibitors for cancer therapy].
Saito H; Miki Y
Gan To Kagaku Ryoho; 2011 Jan; 38(1):12-8. PubMed ID: 21368455
[TBL] [Abstract][Full Text] [Related]
3. Clinical poly(ADP-ribose) polymerase inhibitors for the treatment of cancer.
Lewis C; Low JA
Curr Opin Investig Drugs; 2007 Dec; 8(12):1051-6. PubMed ID: 18058575
[TBL] [Abstract][Full Text] [Related]
4. Inhibition of poly(ADP-ribose) polymerase in cancer.
Plummer ER
Curr Opin Pharmacol; 2006 Aug; 6(4):364-8. PubMed ID: 16753340
[TBL] [Abstract][Full Text] [Related]
5. Poly(ADP-ribose) polymerase inhibitors in cancer treatment: a clinical perspective.
Sandhu SK; Yap TA; de Bono JS
Eur J Cancer; 2010 Jan; 46(1):9-20. PubMed ID: 19926276
[TBL] [Abstract][Full Text] [Related]
6. The potential of PARP inhibitors in genetic breast and ovarian cancers.
Drew Y; Calvert H
Ann N Y Acad Sci; 2008 Sep; 1138():136-45. PubMed ID: 18837894
[TBL] [Abstract][Full Text] [Related]
7. Poly(ADP-ribose) polymerase as a drug target for cardiovascular disease and cancer: an update.
Horvath EM; Szabó C
Drug News Perspect; 2007 Apr; 20(3):171-81. PubMed ID: 17520094
[TBL] [Abstract][Full Text] [Related]
8. The role of poly adenosine diphosphate ribose polymerase inhibitors in breast and ovarian cancer: current status and future directions.
Chionh F; Mitchell G; Lindeman GJ; Friedlander M; Scott CL
Asia Pac J Clin Oncol; 2011 Sep; 7(3):197-211. PubMed ID: 21884432
[TBL] [Abstract][Full Text] [Related]
9. Putting poly (ADP-ribose) polymerase and other DNA repair inhibitors into clinical practice.
Helleday T
Curr Opin Oncol; 2013 Nov; 25(6):609-14. PubMed ID: 24097104
[TBL] [Abstract][Full Text] [Related]
10. Therapeutic potential of poly(ADP-ribose) polymerase inhibitor AG014699 in human cancers with mutated or methylated BRCA1 or BRCA2.
Drew Y; Mulligan EA; Vong WT; Thomas HD; Kahn S; Kyle S; Mukhopadhyay A; Los G; Hostomsky Z; Plummer ER; Edmondson RJ; Curtin NJ
J Natl Cancer Inst; 2011 Feb; 103(4):334-46. PubMed ID: 21183737
[TBL] [Abstract][Full Text] [Related]
11. Chromosomal instability syndromes are sensitive to poly ADP-ribose polymerase inhibitors.
Gaymes TJ; Shall S; Farzaneh F; Mufti GJ
Haematologica; 2008 Dec; 93(12):1886-9. PubMed ID: 18838476
[TBL] [Abstract][Full Text] [Related]
12. [Clinical development of PARP inhibitors].
Toyoda M; Minami H
Gan To Kagaku Ryoho; 2012 Apr; 39(4):519-24. PubMed ID: 22504675
[TBL] [Abstract][Full Text] [Related]
13. BRCA in breast cancer: from risk assessment to therapeutic prediction.
Diamond JR; Borges VF; Eckhardt SG; Jimeno A
Drug News Perspect; 2009 Dec; 22(10):603-8. PubMed ID: 20140280
[TBL] [Abstract][Full Text] [Related]
14. Bcl-2 prevents topoisomerase II inhibitor GL331-induced apoptosis is mediated by down-regulation of poly(ADP-ribose)polymerase activity.
Kuo ML; Shen SC; Yang CH; Chuang SE; Cheng AL; Huang TS
Oncogene; 1998 Oct; 17(17):2225-34. PubMed ID: 9811453
[TBL] [Abstract][Full Text] [Related]
15. The emerging role of poly(ADP-Ribose) polymerase inhibitors in cancer treatment.
Sandhu SK; Yap TA; de Bono JS
Curr Drug Targets; 2011 Dec; 12(14):2034-44. PubMed ID: 21777194
[TBL] [Abstract][Full Text] [Related]
16. Exploiting the Achilles heel of cancer: the therapeutic potential of poly(ADP-ribose) polymerase inhibitors in BRCA2-defective cancer.
Kyle S; Thomas HD; Mitchell J; Curtin NJ
Br J Radiol; 2008 Oct; 81 Spec No 1():S6-11. PubMed ID: 18820000
[TBL] [Abstract][Full Text] [Related]
17. Current development of clinical inhibitors of poly(ADP-ribose) polymerase in oncology.
Ratnam K; Low JA
Clin Cancer Res; 2007 Mar; 13(5):1383-8. PubMed ID: 17332279
[TBL] [Abstract][Full Text] [Related]
18. Poly(ADP-ribosyl)ation in relation to cancer and autoimmune disease.
Masutani M; Nakagama H; Sugimura T
Cell Mol Life Sci; 2005 Apr; 62(7-8):769-83. PubMed ID: 15868402
[TBL] [Abstract][Full Text] [Related]
19. The novel poly(ADP-Ribose) polymerase inhibitor, AG14361, sensitizes cells to topoisomerase I poisons by increasing the persistence of DNA strand breaks.
Smith LM; Willmore E; Austin CA; Curtin NJ
Clin Cancer Res; 2005 Dec; 11(23):8449-57. PubMed ID: 16322308
[TBL] [Abstract][Full Text] [Related]
20. A synthetic lethal therapeutic approach: poly(ADP) ribose polymerase inhibitors for the treatment of cancers deficient in DNA double-strand break repair.
Ashworth A
J Clin Oncol; 2008 Aug; 26(22):3785-90. PubMed ID: 18591545
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
